# A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

> **NCT04630353** · EARLY_PHASE1 · TERMINATED · sponsor: **Hookipa Biotech GmbH** · enrollment: 10 (actual)

## Conditions studied

- HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

## Interventions

- **DRUG:** HB-201 IV
- **DRUG:** HB-201 IV

## Key facts

- **NCT ID:** NCT04630353
- **Lead sponsor:** Hookipa Biotech GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-28
- **Primary completion:** 2023-11-28
- **Final completion:** 2023-11-28
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630353, "A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04630353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*